What is Paragon Genomics?
Headquartered in Hayward, California, Paragon Genomics specializes in the development and commercialization of rapid, high-precision multiplex PCR-based target enrichment solutions. These technologies are essential for the NGS market, enabling researchers and clinicians to streamline complex genomic workflows with high accuracy and efficiency. By simplifying the preparation of samples for sequencing, the company addresses critical bottlenecks in molecular diagnostics and precision medicine, positioning itself as a vital infrastructure provider for the global life sciences sector.
How much funding has Paragon Genomics raised?
Paragon Genomics has raised a total of $8.3M across 2 funding rounds:
Series A
$8M
Debt
$350K
Series A (2017): $8M with participation from HEDA Ventures, Wisemont Capital, and Cowin Venture Capital
Debt (2020): $350K led by PPP
Key Investors in Paragon Genomics
HEDA Ventures
HEDA Ventures is a specialized investment firm with a focus on high-performance manufacturing and industrial technology, bringing deep expertise in supply chain and technical specifications to its portfolio companies.
Wisemont Capital
Wisemont Capital is an early-stage venture capital firm based in Silicon Valley, specializing in investments in AI, SaaS, and automation sectors, providing hands-on guidance to help startups scale globally.
Cowin Venture Capital
Cowin Venture Capital is a prominent Chinese investment firm with a proven track record of guiding enterprises through successful IPOs and fostering long-term growth in the domestic capital market.
What's next for Paragon Genomics?
With the recent influx of capital, Paragon Genomics is well-positioned to scale its manufacturing capabilities and expand its market reach. The company is expected to prioritize the enhancement of its proprietary enrichment platforms to meet the rising demand for high-throughput genomic analysis. As the firm transitions into a more mature phase of its lifecycle, strategic focus will likely shift toward deepening its penetration in clinical diagnostic markets and fostering partnerships that integrate its technology into broader diagnostic ecosystems. This phase of growth is critical for maintaining its competitive edge in the rapidly evolving biotechnology industry.
See full Paragon Genomics company page
